When is ankle repair possible

Ankle cartilage repair is often still possible when the problem is a focal osteochondral lesion of the talus rather than widespread end-stage arthritis. In practice, that means joint-preserving treatment may be on the table before ankle replacement or fusion is ever discussed.

Most people are considered for repair only after imaging has shown a localised talar lesion — usually with ankle radiographs and MRI — and symptoms have continued despite appropriate nonoperative care. These lesions commonly follow trauma, and pain may show up months later, affecting walking, sport and everyday activity.

Whether repair is suitable depends on several features seen on MRI and at surgery: lesion size, whether the defect is contained or unstable, and how much subchondral bone loss or cystic change is present. The DGOU recommendations from 2024 support debridement plus bone marrow stimulation for lesions under 1.0 cm² without bony defect, while larger or more complex lesions may need scaffold augmentation or other joint-preserving techniques. There is no single universal cut-off that fits every ankle.

What doctors need to see before choosing a treatment

The scan findings that change the plan

A patient with a 9 mm medial talar lesion and no obvious cyst on MRI may stay in the “simpler repair” group, because debridement with bone marrow stimulation is more likely to fit a small, contained defect. By contrast, a 1.8 cm² lesion with bone oedema, a subchondral cyst, or a surface that looks unstable on MRI shifts the discussion towards scaffold augmentation, osteochondral transplantation, or another more complex joint-preserving repair.

MRI is useful here because it does more than confirm a defect. It helps define the lesion’s size, how much subchondral bone is involved, whether there is surrounding oedema, and whether the cartilage flap looks unstable. Weight-bearing radiographs still matter, because they show alignment and help identify whether the ankle is being loaded abnormally.

That loading pattern can change the answer. In a 2024 series, patients with large cystic talar lesions and concurrent malalignment improved after realignment surgery, showing that the defect itself is only part of the picture. Medial lesions are common, but location alone is less important than whether the lesion is contained, the bone underneath is intact, and the ankle mechanics are likely to support a repair over time.

This is why the assessment is usually a sorting exercise: lesions that may continue with conservative care, lesions that look repairable with a joint-preserving procedure, and lesions that need reconstruction because the bone loss or loading pattern makes a simple fix unlikely to hold up.

When nonoperative care comes first

Nonoperative care is usually the first step when symptoms are recent, the lesion looks stable, and MRI does not show advanced joint damage. That may include activity modification, physiotherapy, temporary bracing or immobilisation in selected cases, and symptom-guided pain relief.

This approach is most reasonable when pain has been present for only a few months, swelling settles between flares, and the ankle still behaves like a repairable joint rather than one already showing end-stage wear. In that setting, the aim is to calm the lesion and see whether function can improve without an operation.

Persistent pain, repeated swelling, catching, or a failure to progress after a period of conservative care can change the discussion. At that point, the question becomes whether a joint-preserving repair should be used before the ankle moves towards more destructive options such as fusion or replacement. The evidence retrieved here does not support strong claims for injections or biologics in focal talar cartilage loss, so they should not be overstated as substitutes for repair.

Which repair technique may fit the lesion

Matching the operation to the lesion

A small, contained talar defect is often treated differently from a larger or cystic one. Current 2024 DGOU recommendations support debridement with bone marrow stimulation for lesions smaller than 1.0 cm² when there is no bony defect. In practical terms, that keeps the first operative step relatively simple when the cartilage damage is focal and the bone underneath still looks supportive.

Once the defect is larger, the plan may change. For lesions over 1.0 cm², scaffold augmentation can be considered, and AMIC has supportive ankle-specific data in medium-sized stage 3 lesions: in one retrospective multicentre study, average defect size was 1.83 cm², AOFAS scores improved from 71 to 90, and 80% of patients were satisfied at a mean 34-month follow-up.

A different operation is used when there is a repairable osteochondral fragment rather than a worn crater. In that situation, fixation aims to preserve native tissue instead of replacing it. Retrograde drilling is another selective option when the subchondral bone needs treatment but the cartilage surface above is still relatively intact.

For larger, cystic, or previously failed lesions, autologous osteochondral transplantation becomes a stronger consideration. The 2024 recommendations cite good-to-excellent results in 87% of patients, but also note donor-site morbidity of up to 16.9%, which is one reason the choice is usually individual rather than routine.

There is no single cut-off that fits every ankle. Lesion size, bone loss, stability, and whether the defect can still be contained all influence the final decision, so two talar lesions of similar diameter may still need different repairs.

Why bone loss or malalignment can change the plan

Why the surrounding mechanics matter

A talar lesion is not always just a hole in the cartilage surface. If there is subchondral bone loss, a cyst, poor containment, or an unstable edge, a simple marrow-stimulation repair may be less reliable because the damaged bone underneath is not giving the new tissue a stable base. That is one reason the same-sized lesion can be treated differently on two MRI scans taken in 2024 or 2025.

Load across the ankle also matters. In selected patients, correcting abnormal alignment or other loading problems may form part of the joint-preserving plan, rather than treating the defect in isolation. A 2024 case series reported significant pain and function improvement after realignment surgery in patients with large cystic talar lesions and concurrent malalignment, suggesting that the mechanics around the lesion can be as important as the lesion itself.

This is why planning may combine cartilage repair with bone work, fixation, drilling, scaffold-based repair, or realignment. The aim is not only to fill the defect, but to preserve a durable ankle joint that can keep transmitting body weight through the talus more normally over time.

Questions to ask about outcomes and next steps

What to ask at the consultation

A useful consultation usually comes down to five concrete questions in 2024 or 2025: How large is the lesion, is it stable, is there a bony defect or cyst, has treatment already failed, and what rehabilitation will follow? Those details matter because the published evidence supports joint-preserving repair only in selected talar lesions, and the best option is often lesion-specific rather than fixed by one universal rule.

It is also reasonable to ask what would count as success in that case. For some patients, that means less pain on stairs or when running; for others, it is returning to work, sport, or day-to-day walking with fewer flares. The answer depends on the procedure and on the biology of the lesion, so recovery plans are as important as the operation itself.

Comparative evidence between marrow stimulation, scaffold augmentation, fixation, drilling, and osteochondral transplantation remains limited. The 2024 DGOU recommendations and recent clinical series support a stepwise joint-preserving approach, but they do not turn talar cartilage repair into a one-size-fits-all decision.

What this evidence set does not settle is when ankle fusion or replacement becomes the better choice. It focuses on focal osteochondral lesions of the talus, not end-stage ankle arthritis, so the threshold for moving to salvage surgery is outside the scope of these sources.

When the lesion is complex, a specialist assessment helps match the procedure to the scan findings, the bone underneath, and the loading pattern around the ankle. In London, that kind of joint-preservation assessment is available at London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads advanced cartilage and regenerative-medicine care.

1. [1] Author not provided. (2025). Clinical and radiologic outcomes following autologous osteochondral transplantation for lateral osteochondral lesions of the talus. *Journal of Bone and Joint Surgery*, *107*(2). https://doi.org/10.1177/10711007241308576 https://doi.org/10.1177/10711007241308576